vs

Side-by-side financial comparison of Cintas (CTAS) and Danaher Corporation (DHR). Click either name above to swap in a different company.

Cintas is the larger business by last-quarter revenue ($6.4B vs $6.0B, roughly 1.1× Danaher Corporation). Danaher Corporation runs the higher net margin — 17.3% vs 7.8%, a 9.5% gap on every dollar of revenue. On growth, Cintas posted the faster year-over-year revenue change (8.9% vs 3.7%). Over the past eight quarters, Cintas's revenue compounded faster (61.2% CAGR vs 1.8%).

Cintas Corporation is an American corporation headquartered in Mason, Ohio, which provides a range of products and services to businesses including uniforms, mats, mops, cleaning and restroom supplies, first aid and safety products, fire extinguishers and testing, and safety courses. Cintas is a publicly held company traded on the Nasdaq Global Select Market under the symbol CTAS and is a component of the S&P 500 Index.

Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments,...

CTAS vs DHR — Head-to-Head

Bigger by revenue
CTAS
CTAS
1.1× larger
CTAS
$6.4B
$6.0B
DHR
Growing faster (revenue YoY)
CTAS
CTAS
+5.2% gap
CTAS
8.9%
3.7%
DHR
Higher net margin
DHR
DHR
9.5% more per $
DHR
17.3%
7.8%
CTAS
Faster 2-yr revenue CAGR
CTAS
CTAS
Annualised
CTAS
61.2%
1.8%
DHR

Income Statement — Q4 FY2026 vs Q1 FY2026

Metric
CTAS
CTAS
DHR
DHR
Revenue
$6.4B
$6.0B
Net Profit
$502.5M
$1.0B
Gross Margin
83.1%
60.3%
Operating Margin
10.3%
22.6%
Net Margin
7.8%
17.3%
Revenue YoY
8.9%
3.7%
Net Profit YoY
8.4%
7.9%
EPS (diluted)
$1.24
$1.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTAS
CTAS
DHR
DHR
Q1 26
$6.4B
$6.0B
Q4 25
$2.8B
$6.8B
Q3 25
$2.7B
$6.1B
Q2 25
$2.7B
$5.9B
Q1 25
$2.6B
$5.7B
Q4 24
$2.6B
$6.5B
Q3 24
$2.5B
$5.8B
Q2 24
$2.5B
$5.7B
Net Profit
CTAS
CTAS
DHR
DHR
Q1 26
$502.5M
$1.0B
Q4 25
$495.3M
$1.2B
Q3 25
$491.1M
$908.0M
Q2 25
$448.3M
$555.0M
Q1 25
$463.5M
$954.0M
Q4 24
$448.5M
$1.1B
Q3 24
$452.0M
$818.0M
Q2 24
$414.3M
$907.0M
Gross Margin
CTAS
CTAS
DHR
DHR
Q1 26
83.1%
60.3%
Q4 25
50.4%
58.0%
Q3 25
50.3%
58.2%
Q2 25
49.7%
59.3%
Q1 25
50.6%
61.2%
Q4 24
49.8%
59.5%
Q3 24
50.1%
58.7%
Q2 24
59.7%
Operating Margin
CTAS
CTAS
DHR
DHR
Q1 26
10.3%
22.6%
Q4 25
23.4%
22.0%
Q3 25
22.7%
19.1%
Q2 25
22.4%
12.8%
Q1 25
23.4%
22.2%
Q4 24
23.1%
21.8%
Q3 24
22.4%
16.5%
Q2 24
22.2%
20.3%
Net Margin
CTAS
CTAS
DHR
DHR
Q1 26
7.8%
17.3%
Q4 25
17.7%
17.5%
Q3 25
18.1%
15.0%
Q2 25
16.8%
9.3%
Q1 25
17.8%
16.6%
Q4 24
17.5%
16.6%
Q3 24
18.1%
14.1%
Q2 24
16.8%
15.8%
EPS (diluted)
CTAS
CTAS
DHR
DHR
Q1 26
$1.24
$1.45
Q4 25
$1.21
$1.69
Q3 25
$1.20
$1.27
Q2 25
$1.08
$0.77
Q1 25
$1.13
$1.32
Q4 24
$1.09
$1.50
Q3 24
$1.10
$1.12
Q2 24
$4.00
$1.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTAS
CTAS
DHR
DHR
Cash + ST InvestmentsLiquidity on hand
$183.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.8B
Total Assets
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTAS
CTAS
DHR
DHR
Q1 26
$183.2M
Q4 25
$200.8M
Q3 25
$138.1M
Q2 25
$264.0M
Q1 25
$243.4M
Q4 24
$122.4M
Q3 24
$101.4M
Q2 24
$342.0M
Total Debt
CTAS
CTAS
DHR
DHR
Q1 26
Q4 25
$2.4B
$18.4B
Q3 25
$2.4B
$16.9B
Q2 25
$2.4B
$17.4B
Q1 25
$2.0B
$16.5B
Q4 24
$2.0B
$16.0B
Q3 24
$2.0B
$17.5B
Q2 24
$2.0B
$17.0B
Stockholders' Equity
CTAS
CTAS
DHR
DHR
Q1 26
$4.8B
Q4 25
$4.5B
$52.5B
Q3 25
$4.8B
$51.1B
Q2 25
$4.7B
$52.3B
Q1 25
$4.6B
$50.8B
Q4 24
$4.3B
$49.5B
Q3 24
$4.0B
$51.3B
Q2 24
$4.3B
$49.9B
Total Assets
CTAS
CTAS
DHR
DHR
Q1 26
Q4 25
$10.1B
$83.5B
Q3 25
$9.8B
$79.9B
Q2 25
$9.8B
$81.6B
Q1 25
$9.6B
$79.1B
Q4 24
$9.4B
$77.5B
Q3 24
$9.1B
$80.6B
Q2 24
$9.2B
$78.6B
Debt / Equity
CTAS
CTAS
DHR
DHR
Q1 26
Q4 25
0.54×
0.35×
Q3 25
0.51×
0.33×
Q2 25
0.52×
0.33×
Q1 25
0.44×
0.32×
Q4 24
0.47×
0.32×
Q3 24
0.50×
0.34×
Q2 24
0.47×
0.34×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTAS
CTAS
DHR
DHR
Operating Cash FlowLast quarter
$1.6B
$1.3B
Free Cash FlowOCF − Capex
$1.3B
FCF MarginFCF / Revenue
19.7%
Capex IntensityCapex / Revenue
4.7%
4.0%
Cash ConversionOCF / Net Profit
3.12×
1.28×
TTM Free Cash FlowTrailing 4 quarters
$2.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTAS
CTAS
DHR
DHR
Q1 26
$1.6B
$1.3B
Q4 25
$531.2M
$2.1B
Q3 25
$414.5M
$1.7B
Q2 25
$635.7M
$1.3B
Q1 25
$622.0M
$1.3B
Q4 24
$441.4M
$2.0B
Q3 24
$466.7M
$1.5B
Q2 24
$693.0M
$1.4B
Free Cash Flow
CTAS
CTAS
DHR
DHR
Q1 26
$1.3B
Q4 25
$425.0M
$1.7B
Q3 25
$312.5M
$1.4B
Q2 25
$521.1M
$1.1B
Q1 25
$522.1M
$1.1B
Q4 24
$340.0M
$1.5B
Q3 24
$373.8M
$1.2B
Q2 24
$591.1M
$1.1B
FCF Margin
CTAS
CTAS
DHR
DHR
Q1 26
19.7%
Q4 25
15.2%
25.5%
Q3 25
11.5%
22.6%
Q2 25
19.5%
18.4%
Q1 25
20.0%
18.4%
Q4 24
13.3%
23.0%
Q3 24
14.9%
21.0%
Q2 24
23.9%
19.7%
Capex Intensity
CTAS
CTAS
DHR
DHR
Q1 26
4.7%
4.0%
Q4 25
3.8%
5.4%
Q3 25
3.8%
4.8%
Q2 25
4.3%
4.2%
Q1 25
3.8%
4.3%
Q4 24
4.0%
7.9%
Q3 24
3.7%
5.1%
Q2 24
4.1%
5.0%
Cash Conversion
CTAS
CTAS
DHR
DHR
Q1 26
3.12×
1.28×
Q4 25
1.07×
1.77×
Q3 25
0.84×
1.83×
Q2 25
1.42×
2.41×
Q1 25
1.34×
1.36×
Q4 24
0.98×
1.86×
Q3 24
1.03×
1.85×
Q2 24
1.67×
1.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons